How to Get Tresiba in Connecticut: Prescriptions, Telehealth, and Pharmacy Guide

What Is Tresiba and Why Doctors Prescribe It

Tresiba is the brand name for insulin degludec, an ultra-long-acting basal insulin with a half-life exceeding 25 hours and a duration of action beyond 42 hours at steady state. That extended profile lets most patients inject once daily at any consistent time, which improves adherence compared to insulins requiring a strict same-time injection window.

The FDA approved insulin degludec in September 2015 for adults with type 1 and type 2 diabetes, and later for pediatric patients aged one year and older with type 1 diabetes. The approval was supported by the BEGIN trial program, which enrolled more than 14,000 patients across multiple Phase 3 studies. [1]

The DEVOTE cardiovascular outcomes trial (N=7,637) published in the New England Journal of Medicine in 2017 found that insulin degludec was non-inferior to insulin glargine U-100 for major adverse cardiovascular events (MACE), with a hazard ratio of 0.91 (95% CI 0.78 to 1.06, P<0.001 for non-inferiority). [2] DEVOTE also reported a 40% lower rate of severe hypoglycemia with degludec versus glargine (rate ratio 0.60 to 95% CI 0.48 to 0.76, P<0.001). [2] That hypoglycemia advantage is one of the main clinical reasons Connecticut prescribers choose Tresiba over older basal insulins for patients with hypoglycemia unawareness or frequent nocturnal lows.

The American Diabetes Association 2024 Standards of Care classify basal insulin analogues with reduced hypoglycemia risk, including degludec, as preferred options when hypoglycemia is a concern. [3] The Endocrine Society similarly notes that second-generation basal insulins offer a "clinically meaningful reduction in hypoglycemia" compared to first-generation agents. [4]

Connecticut Telehealth Rules for Tresiba Prescriptions

Connecticut permits telehealth prescribing of insulin degludec. No in-person visit is legally required to initiate a Tresiba prescription, provided the prescriber establishes a valid patient-provider relationship under Connecticut General Statutes Section 19a-906 and the federal Ryan Haight Act requirements. [5]

A valid telehealth encounter for a scheduled medication like insulin must include a complete medical history review, a synchronous audio-video evaluation (phone-only is not sufficient for a new controlled or high-risk medication under most insurer contracts), and documented clinical rationale. Prescribers must hold an active Connecticut DEA registration and a Connecticut medical or advanced practice license.

Platforms operating in Connecticut that offer endocrinology or diabetes management services can issue a Tresiba prescription electronically to any Connecticut-licensed pharmacy. The Connecticut Medical Examining Board confirms that NPs and PAs with full prescriptive authority may prescribe Schedule V and non-scheduled medications, which includes insulin degludec, without physician co-signature when operating within their scope. [6]

Patients should confirm that the telehealth platform is licensed specifically in Connecticut before booking, because some national platforms hold licenses in only a subset of states.

What Labs Are Needed Before Starting Tresiba in Connecticut

Most Connecticut prescribers order a standard pre-start panel before writing the first Tresiba prescription. The core tests are a fasting plasma glucose, HbA1c, a basic metabolic panel (BMP) to assess renal function, and a complete blood count if the patient is new to the practice.

HbA1c establishes baseline glycemic control and helps determine the correct starting dose. The American Diabetes Association recommends an HbA1c target of <7% for most non-pregnant adults, though individualized targets between 7% and 8% are appropriate for patients with significant hypoglycemia history or limited life expectancy. [3] Renal function from the BMP matters because insulin clearance changes with CKD, and dose adjustments may be needed at eGFR <30 mL/min/1.73m².

For patients switching from another basal insulin, the prescriber will also want a recent fasting glucose log (minimum three to seven days) and ideally a CGM tracing if available. Type 1 patients transitioning from insulin glargine U-300 to degludec should have a C-peptide level documented to confirm absent endogenous secretion, since the dosing conversion differs from type 2. [7]

The Tresiba FDA prescribing information specifies unit-to-unit substitution when converting from insulin glargine or detemir in type 2 diabetes, but recommends reducing the dose by 20% when converting type 1 patients from glargine U-300 to avoid stacking during the transition week. [8]

How to Get a Tresiba Prescription in Connecticut: Step-by-Step

Getting a Tresiba prescription in Connecticut follows a predictable path regardless of whether you use a telehealth provider or an in-person clinic.

Step 1. Schedule a diabetes-focused visit. Book with an endocrinologist, primary care physician, NP, or PA licensed in Connecticut. Telehealth visits count if the platform holds a Connecticut license.

Step 2. Bring or upload your records. Gather your most recent HbA1c result, current insulin regimen and doses, blood glucose logs, any CGM reports, and a list of current medications including any GLP-1 receptor agonists or SGLT-2 inhibitors you are taking alongside basal insulin.

Step 3. Complete any required labs. If your last HbA1c is older than 90 days, most Connecticut insurers will not process a PA without a current result. LabCorp and Quest both have draw sites throughout Connecticut, and many telehealth platforms can order labs directly.

Step 4. Confirm insurance coverage and PA requirements. Anthem, Aetna, UnitedHealthcare, and Cigna all operate in Connecticut, and each has a separate insulin formulary tier. Tresiba sits on Tier 3 or Tier 4 on most commercial plans, triggering a PA.

Step 5. Submit the prior authorization. Your prescriber's office handles this. Connecticut law (Public Act 21-35) requires insurers to respond to PA requests for urgent medications within 72 hours and standard requests within five business days. [9]

Step 6. Send the prescription to your chosen pharmacy. Once PA is approved, the electronic prescription routes to your preferred pharmacy. Mail-order pharmacies such as Express Scripts or CVS Caremark can ship Tresiba directly to a Connecticut address in one to five business days.

Prior Authorization Requirements in Connecticut

Prior authorization for Tresiba in Connecticut typically requires the following documentation, though exact requirements vary by payer.

Most commercial plans ask for a current HbA1c result (dated within the past 90 days), documentation of at least one failed trial of a preferred formulary basal insulin (usually insulin glargine or detemir), and a clinical note explaining why the patient requires degludec specifically. Common accepted reasons include documented recurrent severe hypoglycemia on glargine, hypoglycemia unawareness confirmed by Clarke Hypoglycemia Awareness Survey score, or provider attestation of inadequate glycemic control despite optimized glargine dosing. [10]

Connecticut Medicaid (HUSKY Health) covers insulin degludec with PA for both type 1 and type 2 diabetes. The HUSKY Health preferred drug list as of 2024 requires step therapy through insulin glargine first for type 2 patients, with an exception pathway available for type 1 patients and for type 2 patients with a documented hypoglycemia history. [11]

The HealthRX clinical team uses a three-criterion PA justification framework for Connecticut patients: (1) at least two documented severe hypoglycemia events in the prior six months on a first-generation basal insulin, or a Clarke score of 3 or higher; (2) HbA1c within target range, confirming the issue is hypoglycemia rather than overall poor control; and (3) provider attestation that flexible dosing timing is medically necessary based on the patient's work schedule or shift-work status. This framework has supported successful PA submissions across multiple Connecticut payers.

If the PA is denied, Connecticut insurers must provide a written denial with the specific clinical criteria not met. Patients have the right to a standard appeal within 45 days of denial and an expedited appeal within 72 hours if the prescriber certifies the medication is urgent. [9]

Tresiba Pharmacy Options in Connecticut

Tresiba (insulin degludec) is commercially available at nearly every major retail pharmacy chain operating in Connecticut, including CVS, Walgreens, Rite Aid, Stop and Shop pharmacy, and ShopRite pharmacy. The flexpens (100 units/mL and 200 units/mL) and vials (100 units/mL) require refrigeration until first use and can be stored at room temperature below 86°F for up to 56 days after opening. [8]

Cash-pay pricing at Connecticut retail pharmacies ranges from approximately $340 to $420 per flexpen box (5 pens per box, 3 mL each) without insurance. Novo Nordisk's My$99Insulin program caps the out-of-pocket cost at $99 per month for commercially insured and uninsured patients who meet income eligibility criteria. [12] Patients should verify current eligibility at NovoCare.com before assuming the cap applies.

Mail-order pharmacies affiliated with major PBMs (Express Scripts, CVS Caremark, OptumRx) can deliver Tresiba to Connecticut addresses. Overnight and two-day cold-pack shipping is available. Packages typically arrive within one to five business days after PA approval.

503A compounding pharmacies licensed in Connecticut can dispense non-commercially-altered insulin degludec preparations (for example, adjusted concentrations for pediatric dosing under provider direction), but the standard commercial Tresiba product does not require compounding and should be dispensed as the FDA-approved brand. [13]

Transferring a Tresiba Prescription to Connecticut

Moving to Connecticut with an active Tresiba prescription from another state is straightforward. Connecticut pharmacies can accept transferred prescriptions from out-of-state pharmacies for non-controlled medications, and insulin degludec is not a controlled substance. Call the Connecticut pharmacy and provide the name, phone number, and prescription number from your current pharmacy. The receiving pharmacist handles the transfer.

If you move to Connecticut and your out-of-state prescriber is not licensed in Connecticut, your transferred prescription must be verified against remaining authorized refills. Connecticut law allows pharmacists to dispense an emergency supply (up to a 30-day supply) of a non-controlled chronic medication when transfer is not possible and the patient demonstrates a documented need, though this varies by pharmacist discretion. [14]

Establishing care with a Connecticut-licensed prescriber within 30 days of relocation is advisable to avoid gaps. Telehealth platforms that hold Connecticut licenses can complete an onboarding visit within days, review your existing Tresiba dose, and issue a new prescription without requiring you to restart PA from zero if your clinical documentation is current.

Dosing and Administration Basics for Connecticut Patients New to Tresiba

Tresiba is injected subcutaneously once daily. The injection can be given at any time of day, but should be given at the same time each day when possible. Unlike insulin glargine U-100 or NPH, Tresiba tolerates dose-timing flexibility of up to 8 hours in either direction without significant pharmacokinetic deviation, which the FLEX trial (N=687) confirmed was non-inferior to fixed-time dosing for HbA1c reduction. [15]

Standard starting doses in the Tresiba prescribing information are: type 2 diabetes naive to insulin, 10 units once daily; type 1 diabetes, approximately one-third of total daily insulin dose as the basal component. [8] Titration follows a "treat-to-target" approach, adjusting by 2 units every three days based on fasting glucose readings, targeting fasting glucose of 80 to 130 mg/dL per ADA 2024 guidelines. [3]

Injection sites in Connecticut patients do not differ from general guidance. Rotate among the abdomen, thigh, and upper arm. Avoid injecting into the same spot twice in a row to reduce lipohypertrophy. The Tresiba flexpen delivers doses from 1 to 80 units in single-unit increments for the U-100 pen and 2 to 160 units in 2-unit increments for the U-200 pen. [8]

Hypoglycemia Risk and Monitoring with Tresiba

Tresiba's lower hypoglycemia rate compared to insulin glargine U-100 is supported by multiple trials beyond DEVOTE. The BEGIN Once Long trial (N=1,030) found a 17% lower rate of nocturnal confirmed hypoglycemia with degludec versus glargine U-100 (rate ratio 0.83, P=0.021). [16] The BEGIN Basal-Bolus Type 1 trial (N=629) showed a 25% reduction in nocturnal hypoglycemia (P=0.021). [17]

Connecticut patients on Tresiba should monitor fasting blood glucose daily during the titration phase (first four to eight weeks). After stabilization, monitoring frequency is guided by glycemic variability, CGM availability, and provider preference. The American Diabetes Association recommends CGM for all patients with type 1 diabetes and for type 2 patients on insulin with frequent hypoglycemia or suboptimal control. [3]

Severe hypoglycemia (requiring third-party assistance) should trigger an immediate contact with the prescribing provider. Connecticut emergency services (911) should be contacted for loss of consciousness or seizure. Glucagon rescue kits, including nasal glucagon (Baqsimi) or injectable glucagon (GlucaGen), should be prescribed alongside Tresiba for any patient with a history of severe hypoglycemia. [18]

Patients should carry a medical ID identifying their insulin use. MedicAlert Foundation and American Diabetes Association provide free or low-cost ID programs. [19]

Insurance Coverage and Cost Reduction in Connecticut

Insurance coverage for Tresiba varies significantly across Connecticut plans. The table below summarizes general tier placement, though patients must verify with their specific plan.

Anthem BCBS Connecticut places degludec on Tier 3 with PA required. Aetna Connecticut plans generally place it on Tier 3 or non-preferred, also with PA. UnitedHealthcare Oxford plans in Connecticut tier it at Tier 4 on some formularies. Connecticut Medicaid (HUSKY Health) covers it with PA as noted above.

Out-of-pocket costs after insurance depend on the tier and the plan's deductible structure. The Novo Nordisk savings card available through NovoCare can reduce co-pays to as low as $10 per month for eligible commercially insured patients. [12] The $35 insulin cap that applies to Medicare Part D under the Inflation Reduction Act as of 2023 applies to Tresiba for Medicare beneficiaries in Connecticut. [20] Connecticut's own insulin pricing legislation (Public Act 19-5) capped monthly insulin cost-sharing at $25 for state-regulated insurance plans prior to the federal cap, and that state cap continues to apply for non-Medicare state-regulated plans. [21]

Connecting with a HealthRX Provider in Connecticut

HealthRX operates as a telehealth platform licensed to prescribe in Connecticut. A provider visit through HealthRX begins with an intake form covering diabetes history, current insulin regimen, recent lab work, and insurance information. Most new patient visits are completed within 24 to 48 hours via synchronous video. If your labs are current (HbA1c within 90 days, BMP within 90 days), a prescription can be sent electronically to your Connecticut pharmacy on the same day as your visit.

HealthRX providers can initiate the prior authorization process on your behalf, submit clinical documentation to your insurer, and assist with Novo Nordisk patient assistance enrollment if cost is a barrier. For patients who have been on Tresiba before and are transferring care to Connecticut, the onboarding visit focuses on confirming the existing dose is appropriate and updating the prescription with your new Connecticut pharmacy.

Your first dose of Tresiba should be injected within two hours of the time you plan to use as your daily injection time going forward, based on the Tresiba prescribing information recommendation to establish a consistent circadian anchor for the basal profile. [8]